How to measure the returns on R&D spending
Summary
The article examines recent economic research that tries to quantify the return on public and private R&D spending. Economists use different methods to track how R&D affects GDP, productivity and long-term prosperity, despite long lags and indirect payoff pathways.
Researchers find surprisingly large returns: conservative estimates suggest every $1 invested in R&D yields roughly $5 in added GDP per person, and public, non-defence R&D has contributed about 20–25% of private-sector productivity growth since World War II. Publicly funded basic research also produces larger cross‑industry spillovers than private R&D — up to three times greater in one study.
The article highlights a worrying policy context: federal R&D funding in the US has declined as a share of GDP (around 0.6% today) while business R&D rose. Proposed 2026 cuts (eg. NIH ~40%, NSF ~57% in the administration proposal) risk slowing productivity growth with effects showing up in 5–10 years.
Key Points
- Conservative estimates by Jones and Summers indicate about a $5 return to GDP per person for every $1 invested in R&D.
- Public, non‑defence R&D has accounted for roughly 20–25% of private‑sector total factor productivity growth since WWII.
- Benefits from public R&D typically appear with a 5–10 year lag and endure for decades.
- Private R&D now exceeds public spending (2023: companies ≈ $700bn vs US government ≈ $172bn), but public R&D yields larger productivity spillovers.
- One study finds public R&D spillovers have about three times the impact on cross‑industry productivity compared with private R&D.
- Long-term declines in federal R&D share (now ~0.6% of GDP) likely contributed to the productivity slowdown since the 1970s.
- Proposed steep cuts to NIH and NSF risk measurable deceleration in US productivity growth within a decade.
Context and relevance
This work reframes the R&D funding debate from anecdotes about past breakthroughs to measurable returns on investment. For policymakers, business leaders and researchers, the evidence suggests public funding of basic science is not just noble but economically productive — especially because it creates broad spillovers that private R&D often does not.
Given debates over fiscal priorities and the proposed 2026 cuts, these findings matter for national competitiveness, long-run GDP per person and the health of innovation ecosystems that underpin sectors from healthcare to AI and quantum technologies.
Why should I read this?
Quick: if you want to understand whether science funding is a luxury or an investment that pays off, this article wraps up the latest economic evidence so you don’t have to wade through academic papers. It shows why slashing research budgets could bite the economy years down the line — and why backing basic science tends to deliver outsized returns.
Author’s take
Punchy and important. The piece turns the ‘funny little science projects’ debate on its head by presenting systematic estimates of social returns. If you care about long-term growth, national competitiveness or sensible budget choices, the research here is compelling — and sobering given the proposed cuts.
